The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Mar 21, 2025•about 1 year ago
Contract Type
contract
RaleighBiotechnology
Description
Opus Genetics, Inc. announced the pricing of an underwritten public offering with gross proceeds of $20 million and concurrent private placement with gross proceeds of $1.5 million, with up to $21.4 million in additional proceeds upon exercise of warrants. The company intends to use the net proceeds to fund clinical development of its lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, as well as for general corporate purposes and working capital.
Company Information
Company
Opus Genetics
Location
Raleigh, North Carolina, United States
About
Ocuphire Pharma, Inc. and Opus Genetics have combined under the Opus Genetics name (Nasdaq: IRD). As a combined company, we are committed to building an innovative, efficient and sustainable clinical-stage ophthalmic biopharmaceutical company leading the development of transformative gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders.
RaleighBiotechnology